Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 6726 (MIR6726) is a small, endogenous, non-coding RNA molecule identified in humans (hsa-miR-6726). MicroRNAs act by binding to complementary sequences within target mRNAs, resulting in repression of target gene expression, either by promoting mRNA degradation or inhibiting translation[2][4]. MIR6726 has been identified as differentially expressed in serum samples from colorectal cancer patients, implicating it as a potential diagnostic biomarker[1]. Predicted target genes of MIR6726 include mitogen-activated protein kinase 1 (MAPK1), suggesting possible involvement in major signaling pathways relevant to tumorigenesis. However, experimental validation of its biological functions and disease associations remains limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 6726 (MIR6726).